Treatment of Chronic Fatigue Syndrome and Fibromyalgia with D-Ribose– An Open-label, Multicenter Study
Jacob Teitelbaum*, 1, Janelle Jandrain2, Ryan McGrew3
Identifiers and Pagination:Year: 2012
First Page: 32
Last Page: 37
Publisher ID: TOPAINJ-5-32
Article History:Received Date: 16/02/2012
Revision Received Date: 10/04/2012
Acceptance Date: 21/04/2012
Electronic publication date: 27/6/2012
Collection year: 2012
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Chronic Fatigue Syndrome and Fibromyalgia (CFS/FMS) are debilitating syndromes affecting ~2- 4% of the population. Although they are heterogeneous conditions associated with many triggers, they appear to have the common pathology of being associated with impaired energy metabolism.
As D-ribose has been shown to increase cellular energy synthesis, and was shown to significantly improve clinical outcomes in CFS/FMS in an earlier study, we hypothesized that giving D-ribose would improve function in CFS/FMS patients.
Design, Location, and Subjects:
An open-label, unblinded study in which 53 US clinics enrolled 257 patients who had been given a diagnosis of CFS/FMS by a health practitioner.
All subjects were given D-ribose (Corvalen™), a naturally occurring pentose carbohydrate, 5-g TID for 3 weeks.